Drug Discovery

Ampersand Capital acquires Purna Pharmaceuticals

Ampersand Capital Partners has acquired Purna Pharmaceuticals, a Belgium-based provider of development and manufacturing services for liquid and semi-solid dosage forms in the pharmaceutical sector.

MSD receives FDA approval for Keytruda combo to treat ovarian cancer

MSD has received the US Food and Drug Administration (FDA) approval for Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), along with paclitaxel, with or without bevacizumab, for ovarian cancer.

THX Pharma and Biocodex sign licensing deal for Batten-1 and TX01 drugs

THX Pharma (Theranexus) and Biocodex have entered a strategic licensing agreement to further the development of two drug candidates, Batten-1 and TX01, targeted at the Batten, Gaucher, and Niemann-Pick type C rare diseases.

Insilico and CMS launch drug discovery collaborations for CNS diseases

Insilico Medicine has announced several AI drug discovery collaborations with China Medical System (CMS) across several projects in central nervous system (CNS) and autoimmune diseases.

REGENXBIO receives FDA response for RGX-121 application

REGENXBIO has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) related to its biologics licence application (BLA) for RGX-121 (clemidsogene lanparvovec) to treat mucopolysaccharidosis II (MPS II), also called Hunter syndrome.

Takeda and Iambic announce $1.7bn deal to advance small molecule programmes

Takeda has entered a multi-year partnership to utilise Iambic’s AI drug discovery models for advancing small molecule programmes, in a deal that could exceed $1.7bn.

Innovent and Lilly to advance new oncology and immunology medicines

Innovent Biologics and Eli Lilly and Company have entered a strategic collaboration agreement to accelerate the global development of new medicines in the fields of oncology and immunology.

Novartis starts construction on new research facility in San Diego, US

Novartis has commenced construction on its new global biomedical research centre in San Diego, California, US, aimed at expanding its drug discovery capabilities.

Apotex and Grünenthal sign deal for Nebido Canadian distribution

Apotex and Grünenthal have finalised a licensing agreement granting Apotex exclusive Canadian rights to Nebido, a long-acting injectable testosterone undecanoate therapy for male hypogonadism.